Biogen

Quick links to important sections

Biogen

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biogen

Understanding Biogen

Biogen is a global biotechnology company that specializes in the discovery, development, and delivery of therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, the organization focuses on advancing scientific research to address complex conditions affecting the brain and central nervous system.

Areas of Focus

The company’s primary research and therapeutic efforts are directed toward several key medical areas, including:

  • Multiple Sclerosis (MS): Developing treatments aimed at managing the symptoms and progression of this chronic inflammatory disease.
  • Spinal Muscular Atrophy (SMA): Providing therapeutic options for this genetic disorder that affects muscle strength and movement.
  • Alzheimer’s Disease: Investigating potential treatments to address the underlying pathology and cognitive decline associated with dementia.
  • Neuropsychiatry and Immunology: Exploring therapies for mood disorders and autoimmune conditions that impact the nervous system.

Scientific Approach

Biogen utilizes specialized expertise in molecular biology and genetics to understand the biological pathways of disease. By focusing on precision medicine and biotechnology, the company aims to create targeted therapies that can modify the course of a disease or improve the quality of life for those with limited treatment options. Their work often involves collaborations with academic institutions and healthcare providers to further the understanding of neuroscience.

Regulatory References

  1. WHO Essential Medicines List
  2. WHO Essential Medicines List for Thiamine

What side effects are possible with Biogen?

Possible Side Effects and Safety Information

The official safety profile for Biogen drugs is derived from extensive clinical trial data and post-marketing surveillance, as documented by governmental regulatory agencies such as the FDA and EMA. Adverse reactions are systematically categorized by Frequency Classification (e.g., Very Common, Common, Rare) and grouped by the System-Organ-Class (SOC) they affect (e.g., Nervous system disorders, Infections and infestations).

Serious Adverse Reactions (SARs) and other clinically significant events are highlighted in the regulatory labeling. For some monoclonal antibody therapies, this includes Amyloid-Related Imaging Abnormalities (ARIA), which can present as swelling (ARIA-E) or small bleeds (ARIA-H) in the brain. ARIA is often asymptomatic but can rarely lead to serious, even fatal, outcomes such as seizures or large intracerebral hemorrhages.

Safety Classifications and Monitoring

Population-Specific Safety Considerations are defined when applicable, such as for use in pregnant patients or those with severe renal or hepatic impairment. The label explicitly notes Safety-Related Restrictions or Limitations, often mandating specific monitoring requirements. For example, products associated with ARIA require a brain MRI scan prior to treatment initiation and at specified intervals during treatment (e.g., before the 5th, 7th, and 14th infusions) to detect these changes. Other monitoring may include laboratory tests for potential renal toxicity or coagulation abnormalities.

Dose- or Exposure-Related Patterns may be documented, such as infusion-related reactions typically occurring with the initial dose.

Regulatory safety summary: The official documentation structures all risks based on verified evidence, classifying the likelihood and nature of potential adverse events. This provides a clear, factual basis for understanding the medicine’s risk profile.

Overdose and Emergency Response

The official regulatory overdose profile for Biogen (Thiamine Hydrochloride) documents that systemic toxicity is generally uncommon with oral ingestion. As a water-soluble vitamin, any excess intake is typically excreted rapidly by the kidneys. Documented toxicity is primarily associated with very high, chronic oral consumption, specifically doses exceeding 3000 milligrams daily.

The most significant severe risk noted in prescribing information involves acute anaphylactic or severe allergic reactions, which are principally associated with the parenteral (injection) route of administration.

When Immediate Medical Help Is Required

These severe systemic reactions can manifest as life-threatening cardiovascular and respiratory complications, including shock, hypotension, and respiratory distress. In the event of a suspected overdose or the onset of severe systemic reactions, government-mandated instructions require that individuals seek immediate medical attention.

Supportive Measures

No specific antidote is known for Thiamine overdose. Management must therefore be symptomatic and supportive. This procedural approach may involve the emergency administration of epinephrine and corticosteroids to treat severe allergic manifestations, requiring hospital monitoring for stabilization.

Therapeutic Uses of Biogen

Biogen (Thiamine B1) is commonly used in situations involving certain distressing symptoms and is relevant for easing the symptomatic burden of Thiamine deficiency, which may present with symptoms related to systemic imbalance.

It is considered relevant in conditions such as Wernicke encephalopathy, high-output cardiac failure (Wet Beriberi), peripheral neuropathy, and malabsorption disorders. The medicine helps address symptom clusters that may become intense or disruptive, particularly those affecting the nervous system (like confusion and numbness) and circulation.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and may assist with managing symptoms related to physical discomfort (chronic fatigue). It supports patients during difficult episodes by easing distress and is applied when appropriate in high-risk groups.


Quick Fact: Easing Symptoms that Interfere with Daily Functioning

Regulatory References

  1. FDA DailyMed product information

Eligibility and Restrictions for Use

Biogen is the company that developed Aduhelm (aducanumab-avwa), an FDA-approved treatment for Alzheimer's disease. Official regulatory documents define who is eligible and who should not use this specific medicine.

Eligibility Criteria

Classification Condition or Population Restrictions / Requirement
Allowed Use Patients with Alzheimer's disease who are in the mild cognitive impairment or mild dementia stage of the disease. The presence of amyloid beta pathology must be confirmed prior to treatment initiation.
Contraindicated Individuals with a history of hypersensitivity to aducanumab-avwa or any component of its formulation. Use is prohibited.
Use Restricted Patients who are ApoE varepsilon 4 homozygotes. These patients have a significantly higher risk of Amyloid Related Imaging Abnormalities (ARIA), including severe cases. Genotype testing is recommended to inform this risk.
Dosing Suspension Patients who develop specific signs of Amyloid Related Imaging Abnormalities (ARIA) or intracerebral hemorrhage greater than 1 cm during treatment. Dosing must be suspended or permanently discontinued based on the severity and type of finding observed on MRI.
Age Restriction Pediatric population. Safety and effectiveness in children have not been established.
Pregnancy/Lactation Pregnant or lactating individuals. No adequate data are available to assess drug-associated risks for the fetus or the breastfed infant.

What should I know about interactions with other medicines?

The interaction profile for Biogen (Thiamine Hydrochloride) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling. Co-administration is formally restricted in cases of known hypersensitivity to Thiamine and is prohibited for the injectable solution when mixed with physically incompatible alkaline agents, such as Acetazolamide Sodium or Aminophylline.

Several medicinal products and substances are documented to alter the body’s exposure to Thiamine. Loop Diuretics, such as Furosemide, cause a pharmacokinetic interaction by increasing the renal clearance of Thiamine, which may reduce its systemic level. Conversely, the binding agent Patiromer decreases the absorption of oral Thiamine in the gastrointestinal tract. To minimize this effect, a mandatory administration timing rule requires a separation of at least 3 hours between taking oral Thiamine and Patiromer. Consumption of Ethanol (Alcohol) is also officially documented to reduce the absorption of the oral form.

Pharmacodynamic interactions include the potential for Thiamine to enhance the effect of Neuromuscular Blocking Agents. Furthermore, Fluorouracil is officially documented as a Thiamine antagonist that reduces the overall efficacy of the medicine. In the context of population-specific cautions, patients with impaired kidney function may face an increased risk of accumulating toxic levels of aluminum present in some parenteral formulations.

Mechanism of Action

How Biogen works: Mechanism of Action

The mechanism of action for Biogen (Thiamine B1) is founded on its role as a necessary precursor to the essential coenzyme, Thiamine Diphosphate (TPP).

Re-establishing Core Cellular Energy Production

TPP acts as an obligate cofactor to activate key mitochondrial enzymes, specifically the Pyruvate Dehydrogenase (PDH) and alpha-Ketoglutarate Dehydrogenase (alpha-KGDH) complexes. This direct enzymatic activation supports the flow of the Tricarboxylic Acid (TCA) cycle and influences the efficient conversion of carbohydrates into Adenosine Triphosphate (ATP) and the metabolism of intermediary substrates, such as lactate. This influence on the core energy cycle supports metabolic activity in cells.

Supporting Neuronal and Cardiac Bioenergetics

The CNS (brain) and the myocardium (heart) are systems sensitive to the activity of TPP-dependent enzymes due to their high energy demands. By supplying the necessary TPP cofactor, the mechanism influences the bioenergetic processes in the brain and heart, impacting the function of neuronal signal transduction and myocardial contractility.

Modulating Biosynthetic and Redox Pathways

TPP also acts as a cofactor for Transketolase (TKT), an enzyme central to the Pentose Phosphate Pathway (PPP). This engagement supports the synthesis of necessary precursors for DNA/RNA building blocks and produces molecules (NADPH) required for cellular redox regulation.

Dosage and Administration Information

Administration Method

The administration of certain therapeutic options, such as Spinraza (nusinersen) and Qalsody (tofersen), involves a specific procedural approach to ensure the medication reaches the intended site. These treatments are delivered via intrathecal bolus injection. This process requires a lumbar puncture, which is a clinical procedure conducted by healthcare professionals who specialize in this technique.


Dosing and Schedule

Treatment plans are structured into two distinct phases: an initial sequence of Loading Doses to establish necessary levels in the body, followed by a Maintenance Dose schedule for long-term management.

Product Loading Doses Maintenance Dose Interval Single Dose Amount
Spinraza 4 doses on Day 0, 14, 28, and 63 Once every 4 months thereafter 12 mg (5 mL)
Qalsody 3 doses at 14-day intervals Once every 28 days thereafter 100 mg (15 mL)

Preparation and Clinical Procedure

Specific preparation steps are required before the procedure can begin. The medication must be allowed to reach room temperature naturally, without the use of external heat. Before administration, the solution is visually inspected for clarity; it should not be used if discoloration or particles are present. Each dose is provided in a single-use vial, and any portion not used during the procedure is discarded.

The administration involves a sequence where a specific volume of Cerebrospinal Fluid (CSF) is removed prior to the injection (5 mL for Spinraza; approximately 10 mL for Qalsody). The medication is then introduced as a bolus injection over a period of 1 to 3 minutes. In instances where a scheduled dose is not administered at the planned time, protocols exist to resume the schedule as soon as possible while maintaining the required intervals between subsequent doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biogen (Thiamine B1)

This overview summarizes the type of research that has been conducted on the use of Thiamine B1 (Biogen), focusing on findings from official sources and clinical trials. This information is intended for context and does not replace medical advice or guidance.


Research Evidence for Acute Deficiency and Neurological Conditions

The research base for using Thiamine B1 in acute deficiency, particularly Wernicke Encephalopathy (WE), is widely reflected in established clinical observations. Studies have primarily involved adults in critical or acute care settings where severe deficiency symptoms were present. More recent short-term randomized controlled trials (RCTs) have been conducted, focusing on whether different treatment protocols and dosages were associated with varying outcomes. Researchers monitored specific neurological function scales and observed how symptoms evolved in the study populations during the acute phases of deficiency.

What remains uncertain: A key area of scientific uncertainty relates to determining the optimal specific dose, route, and duration of treatment that yields the best overall functional outcomes. Additionally, long-term functional outcomes beyond the initial treatment phase are not fully established in the current trial data.


Research Evidence for Chronic Deficiency and Systemic Conditions

Research on chronic Thiamine B1 deficiency, encompassing conditions like Wet Beriberi and Dry Beriberi, relies on a foundation of therapeutic trials and observational studies. These studies examined patterns observed in patients facing conditions characterized by functional limitations. The use of thiamine in these established deficiency states is supported by historical consensus and widely recognized practice.

What remains uncertain: The evidence base for Beriberi lacks large, modern placebo-controlled trials. This is primarily because withholding an essential nutrient from a severely deficient patient is ethically challenging. Furthermore, studies note that patients often present with multiple coexisting nutritional deficiencies, making it challenging to isolate outcomes solely related to thiamine.


Evidence Gaps and Areas of Scientific Uncertainty

The research landscape for Thiamine B1 provides substantial context regarding the nutrient in deficiency correction but includes several recognized limitations. Evidence quality varies across studies, and comparative evidence is lacking against placebo for severe deficiency. Additionally, research in high-stress critical care settings often involves modest sample sizes in trials. Research provides context, but it does not determine whether an individual will respond similarly to the group patterns observed in studies.

Frequently Asked Questions (FAQ)

Common questions about Biogen (FAQ)


Q: What is the average duration of treatment with Biogen?

The duration of therapy is highly dependent on the specific Biogen product and the individual's condition. Regulatory documents indicate that specialized products like Spinraza, Qalsody, and Aduhelm involve long-term maintenance schedules, with studies on some therapies tracking continuous use for several years. The duration of therapy is generally subject to continuous evaluation by the prescribing clinician, and the precise duration of treatment is determined following an individualized medical assessment.


Q: Can Biogen be taken long-term?

Yes, the official treatment regimens for several Biogen therapies are designed to include long-term maintenance phases, often given every few weeks or months. This suggests that long-term use is expected for many patient populations, subject to continuous medical evaluation and benefit assessment.


Q: Is the name 'Biogen' a brand name or a generic name?

Biogen is the name of the company that manufactures and markets various drug products. Each specific medicine, such as Spinraza (generic name: nusinersen) or Aduhelm (generic name: aducanumab-avwa), has its own distinct brand name and generic name.


Q: What are the most common side effects reported for Biogen?

The common side effects are specific to each product, as described in official prescribing information. For example, Spinraza commonly reports headache, back pain, and vomiting, while Aduhelm commonly reports Amyloid-Related Imaging Abnormalities (ARIA) and headache. Qalsody commonly reports pain in the back, limbs, or muscles. The full list of reported common and serious effects is detailed within the official regulatory documentation.


Q: Can Biogen cause problems with sleep or insomnia?

The specific product labels for the specialty therapies, such as Spinraza, Qalsody, and Aduhelm, do not list sleep problems or insomnia as common reported side effects. However, for the high-concentration vitamin Thiamine B1 product, the label may mention a side effect called somnolence, which is a state of drowsiness.


Q: Is Biogen appropriate for older adults or seniors?

The primary indications for Biogen's specialized treatments, such as Aduhelm, are often for conditions found in the adult population, and their regulatory labels do not define specific restrictions based solely on advanced age. For the vitamin Thiamine B1, older adults are recognized in medical literature as a population group that may be at higher risk for nutritional deficiency.


Q: What clinical research has been done on Biogen?

Official regulatory documents for each Biogen product detail the clinical studies that supported its approval, often involving large Phase 3 clinical trials. Research on the vitamin Thiamine B1 primarily focuses on its established role in correcting nutritional deficiencies like Wernicke Encephalopathy. A full overview of research can be found in the regulatory documents for the specific drug.


Q: What phase of clinical trials did Biogen go through before approval?

Most Biogen specialty products received approval following successful Phase 3 clinical trials. Both Spinraza and Qalsody were approved after Phase 3 studies. Aduhelm was granted accelerated approval based on Phase 3 data and is undergoing a follow-up Phase 4 study to confirm benefit.


Q: Are there patient assistance programs available for Biogen?

Yes, Biogen Support Services offer programs designed to help eligible patients navigate financial assistance options for their prescribed treatments. These programs support patients with commercial or government insurance, as well as those who are uninsured or underinsured, to explore potential options.


Q: Does taking Biogen affect a person's ability to drive or operate machinery?

Official labels for specific Biogen specialty drugs like Aduhelm, Spinraza, and Qalsody do not typically include a restriction against driving. However, if using a high-concentration Thiamine B1 product, the label may indicate that possible side effects, such as headache or drowsiness (somnolence), could potentially affect the ability to drive or use heavy machinery.


Q: Does Biogen need to be taken at a specific time of day?

There is generally no mandatory time-of-day restriction for taking these medicines. However, if taking the oral form of Thiamine B1 alongside the drug Patiromer, the official label describes a mandatory minimum 3-hour separation between the two administrations to avoid interfering with the absorption of Thiamine.


Q: Can Biogen cause changes in mood or anxiety levels?

Mood or anxiety changes are not typically listed as direct side effects for many Biogen products. However, in the context of Thiamine B1, the official literature notes that a deficiency of this vitamin is associated with symptoms such as excessive irritability and anxiety. Thiamine supplementation is a strategy utilized to address these deficiency-related effects.


Q: Does Biogen affect fertility in men or women?

Official regulatory product information generally does not contain detailed data on the effect of Biogen's specialty drugs on fertility. For the vitamin Thiamine B1, some limited research has explored its use in fertility treatments, suggesting it may positively influence certain outcomes like the retrieved follicle count in women with specific health conditions.


Q: Is there a maximum amount of time a person can safely use Biogen?

The regulatory treatment protocols for products like Spinraza, Qalsody, and Aduhelm often prescribe a long-term, indefinite maintenance phase of treatment. This means there is no set maximum duration defined in the labeling; safety and continued use are subject to the prescribing clinician's continuous benefit assessment.


Q: What is the difference between Biogen and a biologic medicine?

Biogen is the name of the company that produces the medicines. Several of the company's products, such as Aduhelm, are scientifically classified as a biologic medicine (a monoclonal antibody). Other products like Spinraza and Qalsody are also complex therapies. However, Thiamine B1 is a chemically prepared vitamin supplement and is not considered a biologic medicine.

How should Biogen be stored and disposed of?

How to Store and Dispose of Biogen (Thiamine B1)

The official storage requirements for Biogen (Thiamine Hydrochloride) are defined by the product's formulation.

Storage Conditions:

  • Temperature: Both the oral tablets and the solution for injection must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F).
  • Protection: Oral tablets must be protected from moisture and kept in a tightly closed container.
  • Injection Handling: The solution for injection must not be refrigerated or frozen.

Stability and Safety:

  • The injection is strictly for single-dose use, and any unused portion remaining in the vial must be discarded.
  • All forms of this medicine must be kept out of the reach and sight of children.

Disposal:

Expired or unused Biogen must be disposed of according to local regulations as instructed by a healthcare provider or pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biogen found in:

A-Z Index: